BackOncoSec Medical Overview

OncoSec Medical Net Income

Latest net income for ONCS: $-30M, below the Healthcare sector average of $16B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$6.86M
30.75% YoY

As of Jan 2023

Annual Net Income (TTM)

-$30.14M
26.19% YoY

Trailing 12 months ending Jan 2023

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

OncoSec Medical (ONCS) FAQ

OncoSec Medical (ONCS) currently reports a net income of $-30M as of January 2023. That compares with $-41M in the prior-year period — up 26.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore OncoSec Medical's net income history and peer comparisons.

OncoSec Medical's net income increased from $-41M to $-30M — a 26.2% year-over-year increase (period ending January 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

OncoSec Medical's net income of $-30M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

OncoSec Medical reported $-30M in net income as of January 2023. That compares with $-41M in the prior-year period — up 26.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for OncoSec Medical, and consider following ONCS for alerts when major investors trade the stock.